Ablynx Says No Partner Required To Get Rare Disease Drug To Market

Ablynx says it plans to retain 100% ownership of its thrombotic thrombocytopenic purpura (TTP) therapy, caplacizumab, rather than seek commercialization deals in Europe and the US following Phase III studies.

The company announced in its half year update on Aug.27 that it intends to market caplaczimub, a potential first-in-class anti-von Willebrand Factor (VWF) for the treatment of acquired TTP, on its own in these major regions